Please use this identifier to cite or link to this item:
|Title:||Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report.||Austin Authors:||Wong, Shu Fen;Newland, Lisa;John, Thomas ;White, Shane C||Affiliation:||Austin Health, Department of Medical Oncology, 145 Studley Road, Heidelberg, Victoria, 3084, Australia||Issue Date:||31-Aug-2012||Publication information:||Journal of Medical Case Reports 2012; 6(): 261||Abstract:||Vasculitis has been associated with malignancies, more commonly hematological rather than solid malignancies. Due to the rarity of these conditions and the lack of a temporal association, the relationship between vasculitis and malignancy remains unclear. Paraneoplastic vasculitis as a phenomenon of lung cancer has been described in the literature. To the best of our knowledge, this is the first case report of leukocytoclastic vasculitis being an initial presentation of malignant pleural mesothelioma.We report the case of an 84-year old Greek man who presented to our facility with an erythematous, pruritic and purpuric rash affecting his limbs. This was biopsy-proven to be leukocytoclastic vasculitis and treated conservatively with topical corticosteroids as well as oral prednisolone, with good results. Six months later, he was diagnosed as having malignant pleural mesothelioma. As he remained asymptomatic from his malignancy, no systemic chemotherapy was instituted. He had a recurrence of biopsy-proven leukocytoclastic vasculitis two months after he was diagnosed as having mesothelioma, which again settled with conservative measures.It is important to remain vigilant with regard to the association between leukocytoclastic vasculitis and malignancies. A diagnosis of vasculitis requires a search for malignancies as well as other possible etiologies. This is particularly of relevance when the vasculitis becomes chronic, recurrent or treatment is no longer effective. Should our patient have experienced refractory vasculitis, we would have instituted systemic chemotherapy to treat the underlying malignancy.||Gov't Doc #:||22937937||URI:||http://ahro.austin.org.au/austinjspui/handle/1/11554||DOI:||10.1186/1752-1947-6-261||URL:||https://pubmed.ncbi.nlm.nih.gov/22937937||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 9, 2022
checked on Dec 9, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.